Highlights (cont’d)
Proven efficacy and tolerability
- Over 100,000 human doses with no serious adverse events
- Comparable to injectable
Robust base of potential EMISPHERE® delivery agents
- Library of nearly 2000 EMISPHERE® delivery agents
- 6 different EMISPHERE® delivery agents advanced to clinical testing; 8 therapeutics tested
-
- 2 product candidates have been dosed in large study populations for one month or longer
- 4 active INDs
eligen™ Technology Platform